SCHEMBL5050817

SCHEMBL5050817

CNC(COC)c1ccc(O)c(O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.49
TDP1 Q9NUW8 8/20 0.49
ADRB2 P07550 7/20 0.49
KDM4E B2RXH2 7/20 0.49
HSD17B10 Q99714 6/20 0.49
ADRB1 P08588 5/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
CYP1A2 P05177 4/20 0.49
HIF1A Q16665 4/20 0.49
ADRB3 P13945 4/20 0.49
TSHR P16473 4/20 0.49
MAPK1 P28482 4/20 0.49
MTOR P42345 3/20 0.49
CYP3A4 P08684 3/20 0.49
ADORA3 P0DMS8 3/20 0.49
DRD2 P14416 3/20 0.49
ADRA1D P25100 3/20 0.49
ADRA1A P35348 3/20 0.49
ADRA1B P35368 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5050780 0.83 ADRB2 (0.51) MAPTTDP1ADRB2KDM4EHSD17B10
SCHEMBL7544277 0.80 MAPT (0.53) MAPTTDP1ADRB2KDM4EHSD17B10
SCHEMBL7764700 0.80 MAPT (0.53) MAPTTDP1ADRB2KDM4EHSD17B10
Hydrochloric Acid SCHEMBL6394648 0.79 KDM4E (0.54) MAPTTDP1ADRB2KDM4EHSD17B10
SCHEMBL4989891 0.75 TDP1 (0.50) MAPTTDP1ADRB2KDM4EHSD17B10
SCHEMBL21295303 0.73 KDM4E (0.46) MAPTTDP1ADRB2KDM4EHSD17B10
SCHEMBL27153216 0.73 HDAC6 (0.43) MAPTMAPK1ALDH1A1SLC6A2
SCHEMBL25645952 0.72 ALDH1A1 (0.45) ADRB2KDM4EADRB1DRD2ALDH1A1
SCHEMBL8285875 0.72 ALDH1A1 (0.47) MAPTHSD17B10KMT2ATSHRCYP3A4
SCHEMBL4578363 0.72 ALDH1A1 (0.47) MAPTHSD17B10KMT2ATSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110060045-A1 ANTI-DIABETIC CATARACT COMPOUNDS AND THEIR USES NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2011-03-10 US claimed
EP-2001833-A1 ANTI-DIABETIC CATARACT COMPOUNDS AND THEIR USES National Research Council of Canada (CA) 2008-12-17 EP claimed
WO-2007109882-A1 ANTI-DIABETIC CATARACT COMPOUNDS AND THEIR USES NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2007-10-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110060045-A1 ANTI-DIABETIC CATARACT COMPOUNDS AND THEIR USES INSR, GPR119, ADRB1 MAPT 3973/4885TDP1 3959/4885ADRB2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.